Drug Trial Radar · NCT01981720
Extension Study of PRX-102 for up to 60 Months
Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Jan 16, 2014
Primary completion
Aug 26, 2020
Study completion Nov 9, 2021
Sponsor
- Lead sponsor
- ProtalixIndustry
- Sponsor type
- Industry
- Collaborators
- Chiesi Farmaceutici S.p.A.
- First posted
- Nov 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.
Conditions
- Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa)Biological
PRX-102 1 mg/kg every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03Time frame: Every two weeks up to 60 months
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
University of Florida
Gainesville, Florida
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Johns Hopkins University School of Medicine
Baltimore, Maryland
Institute of Metabolic Disease
Dallas, Texas
O & O Alpan
Fairfax, Virginia
Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C)
Asunción, Paraguay
Hospital de Dia Quiron Zaragoza
Zaragoza, Spain
The Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.